|
Dec 13
|
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
|
|
Aug 10
|
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|
|
Mar 13
|
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript
|
|
Mar 9
|
Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
|